Drug Profile
Research programme: pyruvate kinase inhibitors - Allos Therapeutics
Latest Information Update: 12 Oct 2006
Price :
$50
*
At a glance
- Originator Allos Therapeutics
- Class
- Mechanism of Action Pyruvate kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris; Peripheral vascular disorders
Most Recent Events
- 06 Apr 2004 Suspended - Preclinical for Angina pectoris in USA (unspecified route)
- 06 Apr 2004 Suspended - Preclinical for Peripheral vascular disorders in USA (unspecified route)
- 11 Oct 2002 This programme is still in active development